{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:25:20Z","timestamp":1761863120307},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1019","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,11,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The objective of this study was to review the outcomes of recombinant human endostatin combined with chemoradiotherapy (CRT) as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma (SCC) of the oesophagus.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 38 patients with unresectable but without systemic metastatic SCC of the oesophagus (T4 or stage IVA) were retrospectively studied. 18 patients were treated with recombinant human endostatin combined with 5-fluorouracil (5-FU)\/cisplatin (CDDP)-based CRT and 20 were treated with 5-FU\/CDDP-based CRT alone. Short- and long-term effects including initial treatment response, survival and treatment-related complications were assessed with a median follow-up period of 36.1 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>CRT combined with endostatin resulted in a marked improvement in complete response rates (44.4% vs 30% in the CRT-alone group), and an increase in the 1-year and 3-year overall survival rates (72% vs 50.0% and 32% vs 22.0%, respectively), while the median time to progression was extended to 11.3 months in the combination group vs 8.1 months in the CRT-alone group. There were no treatment-related toxicities that could be attributed specifically to the endostatin, and the toxicities observed across the two groups are probably due to the CRT itself.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The short- and long-term effects of CRT combined with endostatin were an improvement over that of CRT alone in this retrospective cohort study. This combined treatment modality may be a promising treatment modality for the patients with unresectable but without systemic metastatic oesophageal cancer. Further prospective randomised control studies are needed to confirm this finding.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1259\/bjr\/15321801","type":"journal-article","created":{"date-parts":[[2012,8,17]],"date-time":"2012-08-17T04:19:52Z","timestamp":1345177192000},"page":"e1104-e1109","source":"Crossref","is-referenced-by-count":9,"title":["Recombinant human endostatin combined with definitive chemoradiotherapy as primary treatment for patients with unresectable but without systemic metastatic squamous cell carcinoma of the oesophagus"],"prefix":"10.1093","volume":"85","author":[{"given":"Z","family":"Zhong","sequence":"first","affiliation":[{"name":"Department of Cancer Center, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China"},{"name":"Department of Cancer, 285th Hospital of the Chinese People's Liberation Army, Handan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Z","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y","family":"Qing","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Dai","sequence":"additional","affiliation":[{"name":"Department of Cancer Center, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,1,28]]},"reference":[{"key":"2024050213255026900_b1","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1200\/JCO.2005.05.2308","article-title":"Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world.","volume":"24","author":"Kamangar","year":"2006","journal-title":"J Clin Oncol"},{"key":"2024050213255026900_b2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1001\/jama.281.17.1623","article-title":"Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group.","volume":"281","author":"Cooper","year":"1999","journal-title":"JAMA"},{"key":"2024050213255026900_b3","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1053\/j.seminoncol.2004.04.013","article-title":"Treatment of metastatic esophagus and gastric cancer.","volume":"31","author":"Shah","year":"2004","journal-title":"Semin Oncol"},{"key":"2024050213255026900_b4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/bjs.1800810330","article-title":"Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus.","volume":"81","author":"Roder","year":"1994","journal-title":"Br J Surg"},{"key":"2024050213255026900_b5","first-page":"1161","article-title":"Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus.","volume":"6","author":"Shih","year":"2000","journal-title":"Clin Cancer Res"},{"key":"2024050213255026900_b6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ncponc0403","article-title":"Lessons from phase III clinical trials on anti-VEGF therapy for cancer.","volume":"3","author":"Jain","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"2024050213255026900_b7","doi-asserted-by":"crossref","first-page":"5201","DOI":"10.1200\/JCO.2006.08.0887","article-title":"Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.","volume":"24","author":"Shah","year":"2006","journal-title":"J Clin Oncol"},{"key":"2024050213255026900_b8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1126\/science.1062892","article-title":"Cancer. What does radiotherapy do to endothelial cells?","volume":"293","author":"Folkman","year":"2001","journal-title":"Science"},{"key":"2024050213255026900_b9","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.semradonc.2005.08.006","article-title":"Radiation combined with antiangiogenic and antivascular agents.","volume":"16","author":"O'Reilly","year":"2006","journal-title":"Semin Radiat Oncol"},{"key":"2024050213255026900_b10","first-page":"1957","article-title":"Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.","volume":"9","author":"Wachsberger","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2024050213255026900_b11","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ijrobp.2007.07.2325","article-title":"Cetuximab with concurrent chemoradiation for esophagogastric cancer: assessment of toxicity.","volume":"70","author":"Safran","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213255026900_b12","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/37126","article-title":"Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance.","volume":"390","author":"Boehm","year":"1997","journal-title":"Nature"},{"key":"2024050213255026900_b13","doi-asserted-by":"crossref","first-page":"7138","DOI":"10.1200\/jco.2005.23.16_suppl.7138","article-title":"Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients.","volume":"23(16s)","author":"Sun","year":"2005","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"2024050213255026900_b14","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ijrobp.2006.10.030","article-title":"Endostatin improves radioresponse and blocks tumor revascularization after radiation therapy for A431 xenografts in mice.","volume":"67","author":"Itasaka","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213255026900_b15","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1111\/j.1349-7006.2009.01193.x","article-title":"Endostar, a recombined humanized endostatin, enhances the radioresponse for human nasopharyngeal carcinoma and human lung adenocarcinoma xenografts in mice.","volume":"100","author":"Wen","year":"2009","journal-title":"Cancer Sci"},{"key":"2024050213255026900_b16","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3656-4","article-title":"AJCC cancer staging manual.","author":"Greene","year":"2002"},{"key":"2024050213255026900_b17","article-title":"World Health Organization handbook for reporting results of cancer treatment.","author":"World Health Organization","year":"1979"},{"key":"2024050213255026900_b18","author":"National Cancer Institute"},{"key":"2024050213255026900_b19","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.radonc.2008.03.006","article-title":"A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato Digestive Disease & Oncology Group trial (KDOG 0501).","volume":"87","author":"Higuchi","year":"2008","journal-title":"Radiother Oncol"},{"key":"2024050213255026900_b20","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/jjco\/hyh107","article-title":"Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)\/Japan Clinical Oncology Group trial (JCOG9516).","volume":"34","author":"Ishida","year":"2004","journal-title":"Jpn J Clin Oncol"},{"key":"2024050213255026900_b21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/sj.bjc.6600684","article-title":"Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus.","volume":"88","author":"Kaneko","year":"2003","journal-title":"Br J Cancer"},{"key":"2024050213255026900_b22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.7150\/ijms.7.48","article-title":"Effect of dose-escalation of 5-fluorouracil on circadian variability of its pharmacokinetics in Japanese patients with Stage III\/IVa esophageal squamous cell carcinoma.","volume":"7","author":"Kuwahara","year":"2010","journal-title":"Int J Med Sci"},{"key":"2024050213255026900_b23","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1200\/JCO.1999.17.9.2915","article-title":"Definitive chemoradiotherapy for T4 and\/or M1 lymph node squamous cell carcinoma of the esophagus.","volume":"17","author":"Ohtsu","year":"1999","journal-title":"J Clin Oncol"},{"key":"2024050213255026900_b24","first-page":"261","article-title":"Concurrent chemotherapy and radiation therapy for locally advanced carcinoma of the esophagus.","volume":"25","author":"Ohtsu","year":"1995","journal-title":"Jpn J Clin Oncol"},{"key":"2024050213255026900_b25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1081\/CNV-100000068","article-title":"Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer.","volume":"19","author":"Safran","year":"2001","journal-title":"Cancer Invest"}],"container-title":["The British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/85\/1019\/e1104\/57385747\/bjr_15321801.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/85\/1019\/e1104\/57385747\/bjr_15321801.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T13:28:04Z","timestamp":1714656484000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/85\/1019\/e1104\/7450530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11,1]]},"references-count":25,"journal-issue":{"issue":"1019","published-online":{"date-parts":[[2014,1,28]]},"published-print":{"date-parts":[[2012,11,1]]}},"URL":"https:\/\/doi.org\/10.1259\/bjr\/15321801","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,11,1]]},"published":{"date-parts":[[2012,11,1]]}}}